When was Moonlight Therapeutics founded?

Moonlight Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Moonlight Therapeutics located?

Moonlight Therapeutics is headquartered in Atlanta, United States.

Who is the current CEO of Moonlight Therapeutics?

Samirkumar Patel of Moonlight Therapeutics.

How many employees does Moonlight Therapeutics have?

As of Aug 31, 2026, the latest employee count at Moonlight Therapeutics is 8.

Is Moonlight Therapeutics a funded company?

Moonlight Therapeutics is a funded company, having raised a total of $2.42M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2019.

When was the latest funding round of Moonlight Therapeutics?

Moonlight Therapeutics' latest funding was a $***** Grant (prize money) round on Jun 02, 2025, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.22B in funding in 2026 to date.

Where does Moonlight Therapeutics rank among its competitors?

Moonlight Therapeutics ranks 53rd amongst 252 active competitors, of which 73 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Infinimmune, which secured $75M in Aug, 2026.

Who are the top competitors of Moonlight Therapeutics?

Moonlight Therapeutics' top competitors include argenx, Halozyme and Zai Lab. Among them, Infinimmune secured the most recent funding round in August, 2026.

Moonlight Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies for people suffering from food allergies. The company has developed a proprietary platform TASIS (target the drug to the skin’s immune cells), which has a small, minimally invasive dermal stamp that uses microneedles. They are developing their lead candidate which is being investigated for treating peanut allergy.

Website: www.moonlighttx.com/
Social
Email ID: *****@moonlighttx.com

Key Metrics

Founded Year

2017

Location

Atlanta, United States

Stage

Seed

Total Funding

$2.42M in 9 rounds

Latest Funding Round

Grant (prize money), Jun 02, 2025, $*****

Investors

seedToB & 4 more

Ranked

53^rd among 252 active competitors

Employee Count

8 as on Aug 31, 2026

Similar Companies

argenx & 306 more

View Moonlight Therapeutics' full profile

Moonlight Therapeutics has raised a total funding of $2.42M over 9 rounds. Its first funding round was on Apr 01, 2019. Its latest funding round was a Grant (prize money) round on Jun 02, 2025 for $*****. 1 investor participated in its latest round. Moonlight Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Moonlight Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2025	4199255	Grant (prize money)	2518454	9211020	8196185	7759009
Apr 30, 2025	2644226	Grant (prize money)	9611392	3146752	3210879	HHS
Aug 01, 2024	1040314	Seed	7239570	6073533	9303456	1260747

Access funding benchmarks and valuations. Sign up today!

View details of Moonlight Therapeutics's funding rounds and investors

Moonlight Therapeutics' employee count trend

Moonlight Therapeutics has 8 employees as of Aug 26. Here is Moonlight Therapeutics's employee count trend over the years:

Employee count trend for Moonlight Therapeutics

Uncover Moonlight Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Moonlight Therapeutics include argenx, Halozyme and Zai Lab. Here is the list of Top 10 competitors of Moonlight Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	67/100
3rd	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Rock Springs Capital & 9 others	67/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	66/100
5th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, Hercules Capital & 5 others	65/100
6th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	62/100
9th	Infinimmune 2022, Alameda (United States), Series A	Developer of antibody-based drugs to treat various diseases	$87M	Playground Global, Regeneron Ventures & 13 others	62/100
10th	Immunomic Therapeutics 2005, Rockville (United States), Series B	Vaccines for allergy, cancer and infectious disease.	$104M	HLB, Defense.gov & 7 others	62/100
53rd	Moonlight Therapeutics 2017, Atlanta (United States), Seed	Developer of therapies for people suffering from food allergies	$2.42M	NIAID, Georgia Research Alliance & 3 others	51/100